NAD+ (Nicotinamide Adenine Dinucleotide)

Overview: Why NAD+ Is Included

NAD+ (Nicotinamide Adenine Dinucleotide) is technically not a peptide. It is a small-molecule coenzyme-a small organic molecule required by enzymes to catalyze biochemical reactions. Its inclusion on PeptideLibraryHub, a research database focused on peptides, requires explanation.

NAD+ is included because it occupies a central position in the intersection of peptide research, longevity science, and cellular metabolism. Multiple lines of research indicate that:

• NAD+ levels decline significantly with age, suggesting a potential link to aging-related dysfunction
• Peptides like sirtuins and PARPs depend on NAD+ as a critical cofactor for their function
• NAD+ precursors (NMN, NR) are discussed extensively in peptide and longevity research communities
• IV NAD+ therapy is discussed alongside peptide therapeutics in research and biohacking communities
• Understanding NAD+ metabolism is essential to understanding cellular aging and potential therapeutic interventions

NAD+ represents one of the most fundamental molecules in cellular biology, yet it is frequently misunderstood in popular media and research communities. This profile aims to provide accurate, evidence-based information about NAD+, its biological roles, its decline with age, and the evidence (or lack thereof) for therapeutic interventions.

What Is NAD+ and Why Is It Important?

Chemical Structure and Basic Function

NAD+ (the oxidized form) and NADH (the reduced form) are interconvertible coenzymes derived from the B vitamin niacin (vitamin B3). NAD+ exists in two forms in cells: free NAD+ and bound NAD+ (bound to proteins). The NAD+/NADH ratio determines the oxidation-reduction (redox) state of cells, which regulates the activity of multiple metabolic pathways.

Chemically, NAD+ consists of two nucleotides joined by a phosphate group: an adenine nucleotide and a nicotinamide nucleotide. The nicotinamide ring is the reactive center where NAD+ accepts electrons during enzymatic reactions, converting to NADH. NADH then donates these electrons in other reactions, regenerating NAD+. This continuous cycling between oxidized (NAD+) and reduced (NADH) forms is fundamental to cellular energy metabolism.

500+ Enzymatic Reactions

NAD+ serves as a cofactor for over 500 known enzymes (called NAD+-consuming enzymes), making it one of the most versatile coenzymes in biology. These include:

• Glycolysis enzymes: Converting glucose to pyruvate, the first step of energy production
• Citric acid cycle (TCA cycle) enzymes: The central metabolic hub that extracts energy from nutrients
• Oxidative phosphorylation (electron transport chain): The machinery that generates ATP, cellular energy
• Sirtuins (SIRT1-7): NAD+-dependent deacetylases involved in longevity and stress responses
• PARPs (poly-ADP-ribose polymerases): NAD+-consuming enzymes involved in DNA repair
• CD38/CD157: NAD+-consuming ectoenzymes involved in immune signaling and calcium signaling
• ADPRCs (ADP-ribosyl cyclases): Enzymes involved in cellular signaling

The centrality of NAD+ to cellular metabolism means that its availability directly impacts the rate and efficiency of energy production and the activity of critical regulatory pathways.

NAD+ and Aging: The Decline with Age

Longitudinal research has documented that NAD+ concentrations decline significantly with age across tissues. Studies by Yoshino and colleagues estimate that NAD+ levels in humans decline by approximately 50% between ages 40-60, with further decline thereafter. This age-dependent decline appears to be a conserved phenomenon across species, from yeast to mammals. The decline occurs due to:

• Decreased NAD+ synthesis (reduced activity of enzymes that generate NAD+ from tryptophan)
• Increased NAD+ consumption by CD38 and other NAD+-consuming enzymes
• Mitochondrial dysfunction (mitochondria are major consumers and producers of NAD+)
• Accumulation of cellular damage and stress signals that consume NAD+ in repair processes (PARP activation)

The correlation between NAD+ decline and aging has led to the hypothesis that restoring NAD+ levels might slow or reverse aging-related decline. This hypothesis remains unproven in humans but has motivated substantial research.

Mechanisms of Action: Sirtuins, PARPs, and CD38

Sirtuins: NAD+-Dependent Deacetylases

Sirtuins (silent information regulators) are a family of seven proteins (SIRT1-7) with NAD+-dependent enzymatic activity. They function as deacetylases, removing acetyl groups from target proteins. Acetylation and deacetylation are post-translational modifications that regulate protein function. Sirtuins are involved in stress resistance, metabolic homeostasis, and longevity.

SIRT1 is the most extensively studied sirtuin. It regulates the deacetylation of transcription factors and metabolic enzymes in response to stress and caloric restriction. Increased SIRT1 activity is associated with improved metabolic health, cellular stress resistance, and extended lifespan in model organisms. SIRT1 activity is dependent on NAD+ availability, suggesting that increasing NAD+ could enhance SIRT1-mediated health effects.

Other sirtuins (SIRT2-7) localize to different cellular compartments (mitochondria, nucleolus, etc.) and regulate distinct biological processes. The dependence of sirtuins on NAD+ suggests that NAD+ decline with age may impair sirtuin-mediated stress resistance and metabolic adaptation.

PARPs: DNA Repair and Stress Response

Poly-ADP-ribose polymerases (PARPs) are NAD+-consuming enzymes that catalyze the transfer of ADP-ribose groups onto proteins in response to DNA damage. This ADP-ribosylation activates DNA repair machinery, helping cells repair damage from oxidative stress, radiation, and other insults. PARP1 is the most abundant PARP.

Chronic or excessive PARP activation (from accumulated DNA damage) consumes NAD+, reducing the available pool for sirtuins and other NAD+-dependent processes. In aging organisms with accumulated DNA damage, excessive PARP activation may deplete NAD+ pools, impairing both DNA repair and sirtuin function-a potential vicious cycle in aging.

CD38: NAD+ Consumption and Calcium Signaling

CD38 (cluster of differentiation 38) is an ectoenzyme on cell surfaces that catalyzes the conversion of NAD+ to ADP-ribose, consuming NAD+ in the process. CD38 is involved in immune signaling and calcium mobilization. CD38 expression increases with age and in inflammatory conditions, potentially contributing to age-related NAD+ depletion.

NAD+ and Metabolic Health

NAD+ availability directly impacts the efficiency of ATP generation through oxidative phosphorylation. Cells with adequate NAD+ produce energy efficiently; cells with depleted NAD+ experience impaired ATP production, potentially contributing to metabolic dysfunction, insulin resistance, and mitochondrial disease. Restoring NAD+ in aging organisms might improve mitochondrial ATP production and metabolic efficiency.

NAD+ Decline with Age: Causes and Consequences

The Aging Curve

Research by David Sinclair, Charles Brenner, Shin-ichiro Imai, and colleagues has documented the age-dependent decline in NAD+ across multiple tissues. The decline appears to accelerate in middle age (around age 40-50), with NAD+ levels reaching approximately 50% of young adult levels by age 60. The decline varies across tissues, with some tissues (muscle, liver, pancreas) showing steeper declines than others.

Why NAD+ Declines

Reduced NAD+ Synthesis: NAD+ is synthesized from the amino acid tryptophan through the de novo synthesis pathway (kynurenine pathway). Age-related decline in the expression and activity of enzymes in this pathway reduces NAD+ production. Additionally, the salvage pathway (recycling NAD+ precursors) may be impaired with age.

Increased NAD+ Consumption: As organisms age, they accumulate DNA damage from oxidative stress, radiation, and other sources. This triggers PARP activation and increased ADP-ribosylation, consuming NAD+ in DNA repair. Additionally, CD38 expression increases with age and in inflammatory conditions, increasing NAD+ consumption. The net result is a shift toward NAD+ depletion.

Mitochondrial Dysfunction: Aging is characterized by accumulating mitochondrial dysfunction. Because mitochondria are major sites of NAD+ regeneration from NADH, mitochondrial dysfunction impairs NAD+ regeneration. This creates a vicious cycle: NAD+ depletion impairs mitochondrial ATP production, worsening mitochondrial dysfunction, further impairing NAD+ regeneration.

Consequences of NAD+ Decline

Impaired ATP Production: NAD+ depletion impairs the efficiency of glycolysis, the TCA cycle, and oxidative phosphorylation, reducing ATP production. Tissues with high energy demands (muscle, brain, heart) are particularly vulnerable. This contributes to age-related muscle weakness, cognitive decline, and cardiac dysfunction.

Impaired Sirtuin Function: Reduced NAD+ availability limits SIRT1-7 activity, impairing their protective effects on metabolism and stress resistance. This may contribute to age-related metabolic dysfunction, insulin resistance, and reduced stress resistance.

Impaired DNA Repair: Although NAD+ depletion itself impairs DNA repair, the relationship is complex. While PARP activation consumes NAD+, PARP is required for DNA repair. The balance between NAD+ consumption and the need for DNA repair becomes critical in aging.

Increased Inflammation: NAD+-dependent immune regulation is impaired, potentially contributing to age-related inflammation ("inflammaging"). CD38-mediated NAD+ consumption increases, creating a pro-inflammatory state.

NAD+ vs. NMN vs. NR: Understanding the Differences

NAD+ Directly vs. Precursors

NAD+ itself is a relatively large molecule with a molecular weight of 663 Da. When administered as an IV infusion (IV NAD+ therapy), it enters the bloodstream directly and can be utilized by cells. However, oral NAD+ has poor bioavailability-the molecule is too large and polar (charged) to be effectively absorbed through the gastrointestinal tract.

To overcome this bioavailability limitation, research has focused on NAD+ precursors-smaller molecules that can be absorbed orally and converted to NAD+ inside cells. The two most extensively studied precursors are:

NMN (Nicotinamide Mononucleotide)

NMN is a nucleotide composed of nicotinamide, a ribose sugar, and a phosphate group. It is one step in the NAD+ synthesis pathway. NMN has a molecular weight of 334 Da, making it smaller and more absorbable than NAD+ itself. Preclinical studies in mice have shown that oral NMN is absorbed in the intestine, enters cells, and is converted to NAD+ through the enzyme NAMPT (nicotinamide phosphoribosyltransferase).

NMN has been studied in animal models of aging, metabolic disease, and neurodegeneration, with reports of improvements in mitochondrial function, glucose tolerance, and cognition. Several human clinical trials examining oral NMN supplementation are underway (as of April 2026), examining effects on glucose metabolism, vascular function, and muscle strength in healthy adults and older populations.

NR (Nicotinamide Riboside)

NR is a nucleoside (ribose sugar + nicotinamide without the phosphate group). It has a molecular weight of 270 Da, making it even smaller than NMN. Like NMN, NR is absorbed orally, enters cells, and is converted to NAD+ through the salvage pathway. NR was discovered by Charles Brenner's laboratory at the University of Iowa.

NR has been studied in animal models and human clinical trials. The first marketed supplement containing NR (NIAGEN) was approved as a dietary supplement. Human studies of NR show mixed results: some studies report improvements in metabolic markers or muscle function in older adults, while others show minimal effects in healthy adults. Clinical trial results remain heterogeneous, with significant variation depending on the population, dose, and outcome measured.

Comparison: Advantages and Limitations

• IV NAD+: Highest bioavailability and directly increases NAD+ levels systemically; cannot be given orally; requires medical supervision; most expensive option
• NMN: Smaller than NAD+, better oral bioavailability than NAD+; conversion to NAD+ requires NAMPT; availability as supplement is increasing; some regulatory uncertainty
• NR: Smallest of the three, marketed as dietary supplement; less direct than IV NAD+; extensively studied in clinical trials; commercial availability established (NIAGEN brand)

The choice of which form to use (if any) depends on the goal, bioavailability concerns, cost, and regulatory status. As dietary supplements, NMN and NR exist in a regulatory gray zone-they are not approved drugs, but they are marketed as dietary supplements under weaker regulatory scrutiny than FDA-approved drugs.

IV NAD+ Therapy: Clinical Use and Research

What Is IV NAD+ Therapy?

IV NAD+ therapy involves intravenous infusion of NAD+ in saline solution, typically administered over 2-4 hours in a medical or clinical setting. IV NAD+ directly increases blood and tissue NAD+ levels, bypassing the bioavailability limitations of oral NAD+.

Addiction Recovery

One of the most researched applications of IV NAD+ therapy is addiction recovery. The rationale is that addiction involves dysregulation of dopaminergic systems and mitochondrial dysfunction. By restoring NAD+ levels, the theory proposes that mitochondrial function can be restored, reducing withdrawal symptoms and cravings. Research by Braidy and colleagues has examined IV NAD+ therapy for alcohol dependence and opioid addiction.

Some preliminary studies report that IV NAD+ therapy may reduce withdrawal symptoms and craving intensity compared to standard addiction treatment protocols. However, the evidence base is limited, and many studies have methodological limitations (small sample sizes, lack of blinded controls). IV NAD+ therapy for addiction remains investigational and is not standard medical treatment.

Chronic Fatigue and Mitochondrial Disease

Given NAD+'s central role in ATP production, IV NAD+ therapy has been proposed for chronic fatigue syndrome (CFS/ME) and primary mitochondrial disease. The logic is that increasing NAD+ might improve mitochondrial ATP production and reduce fatigue. However, published clinical evidence for IV NAD+ in these conditions is minimal, consisting mostly of case reports and anecdotal accounts rather than rigorous clinical trials.

Neurodegenerative Disease

Some researchers have examined IV NAD+ therapy for neurodegenerative conditions including Parkinson's disease and Alzheimer's disease, based on the hypothesis that improving neuronal ATP production might slow neuronal death. However, published clinical evidence is limited.

Adverse Effects of IV NAD+ Infusion

IV NAD+ infusion commonly causes transient side effects during or shortly after infusion:

• Nausea: Very common during infusion, typically resolves after infusion completion
• Cramping: Abdominal cramping and discomfort, typically transient
• Chest tightness or pressure: Reported during or after infusion, typically resolves quickly
• Flushing: Facial flushing during infusion
• Headache: Post-infusion headache reported in some patients

These effects are generally mild to moderate, dose-dependent, and transient. Serious adverse events are uncommon, though are possible with rapid infusion or excessive doses. Long-term safety data from repeated IV NAD+ infusions is limited.

Clinical Trial Status

As of April 2026, multiple clinical trials are examining IV NAD+ therapy and NAD+ precursors for various indications. These include trials for chronic fatigue, addiction, metabolic disease, and cognitive function. However, most trials remain preliminary in nature, with results not yet published in major peer-reviewed journals.

Commonly Studied Dosing Protocols

In research literature and clinical trials, NAD+ precursors (primarily nicotinamide mononucleotide [NMN] and nicotinamide riboside [NR]) have been examined using diverse dosing regimens, reflecting the early stage of clinical investigation and the lack of standardized protocols. The following represents commonly discussed dosing ranges based on published and ongoing clinical trials:

Oral NAD+ Precursors (NMN)

Reported dosing ranges: 250 mg to 1,000 mg daily (oral tablet or powder), typically taken once daily in the morning. Some studies use multiple divided doses. Cycle length: Studies typically involve continuous daily dosing for 4–12 weeks, though some longer-term investigations are ongoing. Route: Oral (capsule, tablet, or powder). Evidence status: Multiple small human trials have examined NMN in the 250–1,000 mg/day range for metabolic, vascular, and muscle function outcomes (e.g., PubMed studies on NMN in glucose tolerance and endothelial function). However, optimal dosing for specific indications has not been established, and no head-to-head dose-response studies have been published in high-impact journals. Most positive findings come from small, short-duration trials.

Oral NAD+ Precursors (NR)

Reported dosing ranges: 250 mg to 2,000 mg daily (oral), typically taken once daily or divided. Cycle length: Studies typically involve continuous daily dosing for 4–12 weeks. Route: Oral. Evidence status: NR has been studied in several human trials for vascular health, metabolic parameters, and muscle function at doses ranging from 500 mg to 2,000 mg/day. Published studies are limited in number and sample size, and results have been mixed. Key published trials include Martens et al. (2018) demonstrating that 1,000 mg/day NR for 6–8 weeks is well-tolerated and roughly doubles whole-blood NAD+ in healthy middle-aged and older adults (PMID 29599478); a later randomized trial evaluating 500 mg twice daily for elevated systolic blood pressure and arterial stiffness (PMID 35620522); and the NICE randomized trial in peripheral artery disease using 1,000 mg/day for 6 months (PMID 38871717).

IV NAD+ Therapy

Reported dosing ranges: 500 mg to 10,000 mg per infusion, administered via IV. Frequency: Typically 2–5 times per week, depending on clinical context and trial design. Cycle length: Treatment cycles often involve 4–8 weeks of regular infusions, potentially followed by maintenance protocols. Route: Intravenous infusion (medical setting required). Evidence status: IV NAD+ therapy is used clinically in some contexts (particularly for chronic fatigue and addiction treatment) but has limited published human trial data. Dosing ranges are based on clinical practice protocols rather than rigorous dose-response studies. A 2023 systematic review evaluated safety and effectiveness of NAD+ across clinical conditions including chronic fatigue syndrome, Parkinson's disease, and age-related decline, concluding that evidence for IV protocols remains limited and heterogeneous (PMID 37971292). A 2024 randomized placebo-controlled pilot directly compared acute single-dose NR IV (500 mg), NAD+ IV (500 mg), and oral NR in healthy adults (Niagen+ IV pilot, medRxiv 2024). Additional IV NAD+ studies are registered at ClinicalTrials.gov.

Factors Affecting NAD+ Precursor Efficacy

Several factors complicate NAD+ dosing interpretation: bioavailability varies between oral formulations, cellular uptake varies among tissues, baseline NAD+ levels differ between individuals, age and metabolic status affect NAD+ metabolism, and most human trials have been small and short-duration. The assumption that higher doses produce greater effects has not been rigorously tested in dose-response studies.

Evidence Status: Published human studies of NAD+ precursor dosing are limited in number and sample size. While multiple trials have examined dosing in the ranges above, optimal doses for specific indications have not been established through rigorous head-to-head comparison. The most rigorous evidence exists for NMN and NR in metabolic and vascular contexts, but effect sizes have typically been modest.

Clinical Trials and Research Status

Ongoing Clinical Trials (as of April 2026)

Multiple clinical trials are examining NAD+ precursors (primarily NMN and NR) in diverse populations:

• NMN in metabolic health: Trials examining effects on glucose tolerance, insulin sensitivity, and lipid metabolism in healthy adults and those with metabolic dysfunction
• NMN/NR in vascular function: Trials examining effects on endothelial function, blood pressure, and arterial stiffness
• NR in muscle strength: Trials examining effects on muscle power and function in older adults
• IV NAD+ in addiction recovery: Trials examining IV NAD+ for opioid and alcohol dependence
• NAD+ boosters in mitochondrial disease: Some trials examining NAD+ precursors in genetic mitochondrial disease

Heterogeneous Results

Published studies of NMN and NR supplementation show mixed results. Some studies report benefits (improved glucose tolerance, enhanced vascular function, increased muscle strength in older populations), while others show no significant effects or effects only in specific subgroups. This heterogeneity may reflect differences in:

• Study populations (healthy young adults vs. older adults vs. patients with metabolic disease)
• Doses employed (varying from 250 mg to 1000+ mg daily)
• Duration of treatment (days to months)
• Outcome measures (different endpoints may respond differently)
• Study quality and risk of bias

Evidence Quality

While clinical trials examining NAD+ precursors are increasing, the overall evidence quality remains moderate to low by pharmaceutical standards. Most studies have small sample sizes, short durations, and heterogeneous results. Larger, longer, more rigorous trials are needed to establish whether NMN or NR supplementation produces clinically meaningful benefits in various populations.

Safety Profile: NMN, NR, and IV NAD+

NMN and NR Oral Supplements: Short-Term Safety

In short-term clinical trials (days to months), NMN and NR oral supplements are generally well-tolerated with minimal adverse effects. Reported side effects are uncommon and typically mild, including occasional gastrointestinal effects (nausea, diarrhea) or headache. No serious adverse events have been documented in published clinical trials.

IV NAD+ Therapy: Acute Side Effects

As detailed above, IV NAD+ infusion commonly causes transient side effects during or shortly after infusion (nausea, cramping, chest tightness), which are typically dose-dependent and resolve quickly. Serious adverse events are rare but possible, particularly with rapid infusion or excessive doses.

Theoretical Long-Term Safety Concerns

While short-term safety appears acceptable, several theoretical concerns about long-term NAD+ boosting remain unanswered:

• Effects on cancer risk: NAD+ supports cell proliferation and survival through sirtuins and other mechanisms. Chronic elevation of NAD+ could theoretically promote cancer cell growth. This has not been studied in humans receiving long-term NAD+ supplementation.
• Effects on immune function: CD38 is involved in immune signaling, and NAD+ availability affects immune responses. The long-term effects of chronically elevated NAD+ on immune function, susceptibility to infection, and immune tolerance are unknown.
• Off-target effects: NAD+ is a substrate for multiple enzymes beyond sirtuins and PARPs. Chronic elevation might affect other NAD+-consuming pathways in unexpected ways.
• Tolerance or adaptation: Chronic NAD+ supplementation might trigger compensatory changes in NAD+ synthesis or consumption, reducing the long-term efficacy of supplementation.

None of these theoretical concerns have been empirically validated, but they highlight the need for long-term safety monitoring if NAD+ supplementation becomes widespread.

Interaction Potential

NAD+ is involved in numerous metabolic pathways, so potential drug interactions are possible. Individuals taking medications affecting mitochondrial function, sirtuin-dependent pathways, or NAD+ metabolism should consult healthcare providers before starting NAD+ supplementation.

Stacking Considerations

In research community discussions, NAD+ precursors (NMN and NR) are frequently described in multi-agent "longevity" or "bioenergetic optimization" stacking protocols, combined with other NAD-dependent pathway-supporting compounds and peptides. The proposed rationale is that NAD+ supplementation could be complemented by agents supporting sirtuins (NAD+-dependent enzymes), mitochondrial function, or other aging-related pathways. However, no published human studies have examined the safety or efficacy of NAD+ precursors combined with other peptides, supplements, or pharmaceuticals in systematic stacking protocols.

Commonly Discussed Research Combinations

Reported protocols in research contexts sometimes describe NAD+ precursors stacked with sirtuins activators, resveratrol, mitochondrial-support peptides (MOTS-C, SS-31), NMN/NR together, or other longevity-related compounds. The theoretical basis is that simultaneous support of NAD+-dependent metabolism, sirtuins activation, and mitochondrial biogenesis might produce additive anti-aging benefits. Other discussions involve combining NAD+ precursors with neuroprotective or cognitive-support peptides in brain-health contexts. These combinations remain speculative, based on mechanistic reasoning about aging and metabolism without human validation of safety or efficacy in combination.

Pharmacological Considerations

NAD+ is a central metabolic cofactor involved in hundreds of enzymatic reactions. Combining NAD+ precursors with multiple other agents affecting NAD+-dependent pathways, mitochondrial metabolism, or sirtuins introduces unknown risks: excessive metabolic signaling, dysregulation of energy-dependent processes, potential interactions affecting cellular redox balance, and systemic off-target effects. The notion that "more NAD+" combined with multiple other longevity agents equals better outcomes lacks human evidence.

Evidence Status: No published human studies have examined NAD+ precursors (NMN or NR) combined with other peptides, sirtuins activators, or compounds in systematic stacking protocols. All reported combination discussions represent theoretical extrapolations without clinical evidence of safety or efficacy.

Frequently Asked Questions

Side Effects & Safety Profile

NAD+ supplementation takes several forms (oral NMN/NR, IV NAD+ infusion, subcutaneous NAD+), each with different side effect profiles. The data below reflects published clinical trial data from NMN and NR studies, as well as clinical reports from IV NAD+ infusion protocols.